Table 1 Demographic and clinical characteristics according to valid or missing values of HbA1c, FBG and follow-up.

Age, mean ± SD

58 ± 14

58 ± 13

58 ± 14

0.567

58 ± 13

57 ± 14

0.114

58 ± 13

56 ± 14

0.015

Male, n (%)

1218 (68%)

519 (71%)

699 (65%)

0.007

748 (69%)

470 (65%)

0.067

1024 (68%)

194 (67%)

0.817

BMI, mean ± SD

25.6 ± 4.2

25.6 ± 4.0

25.5 ± 4.3

0.687

25.6 ± 3.8

25.5 ± 4.6

0.674

25.5 ± 4.2

25.7 ± 3.9

0.588

Systolic BP (mm Hg), mean ± SD

169 ± 29

165 ± 25

172 ± 31

 < 0.001

168 ± 28

171 ± 31

0.031

170 ± 29

167 ± 29

0.250

Diastolic BP (mm Hg), mean ± SD

97 ± 17

96 ± 17

98 ± 20

 < 0.001

98 ± 18

97 ± 19

0.066

98 ± 19

97 ± 19

0.537

Prior ischemic stroke, n (%)

259 (14%)

113 (16%)

146 (14%)

0.259

156 (14%)

103 (14%)

0.919

231 (15%)

28 (10%)

0.013

Coronary heart disease, n (%)

34 (2%)

14 (2%)

20 (2%)

0.930

19 (2%)

15 (2%)

0.626

32 (2%)

2 (1%)

0.103

History of hypertension, n (%)

1320 (73%)

545 (75%)

775 (73%)

0.391

798 (74%)

522 (73%)

0.837

1112 (74%)

208 (72%)

0.569

History of diabetes mellitus, n (%)

272 (15%)

132 (18%)

140 (13%)

0.003

159 (15%)

113 (16%)

0.587

234 (15%)

38 (13%)

0.307

History of dyslipidemia, n (%)

178 (10%)

83 (11%)

95 (9%)

0.077

102 (9%)

76 (11%)

0.449

152 (10%)

26 (9%)

0.576

Use of anticoagulation, n (%)

18 (1%)

9 (1%)

9 (1%)

0.511

14 (1%)

4 (1%)

0.189

16 (1%)

2 (1%)

0.643

Use of antiplatelet agent, n (%)

267 (15%)

116 (17%)

151 (17%)

0.648

163 (16%)

104 (18%)

0.301

245 (18%)

22 (9%)

0.001

Current smoking, n (%)

572 (36%)

262 (36%)

310 (33%)

0.252

373 (35%)

199 (33%)

0.501

495 (35%)

77 (32%)

0.581

Current drinking, n (%)

662 (37%)

312 (44%)

350 (37%)

0.004

401 (38%)

261 (42%)

0.128

569 (40%)

93 (39%)

0.705

GCS score, median (IQR)

14 (8–15)

14 (12–15)

12 (6–15)

 < 0.001

14 (11–15)

12 (6–15)

 < 0.001

14 (8–15)

14 (8–15)

0.175

NIHSS score, median (IQR)

11 (4–21)

8 (3–14)

14 (5–25)

 < 0.001

10 (3–17)

14 (5–27)

 < 0.001

11 (4–21)

11 (4–20)

0.490

Location of hematoma, n (%)

0.002

 < 0.001

0.623

   Supratentorial lobe

367 (20%)

153 (22%)

214 (26%)

221 (22%)

146 (30%)

324 (25%)

43 (22%)

Supratentorial deep location

970 (54%)

469 (69%)

501 (61%)

707 (69%)

263 (54%)

837 (64%)

133 (67%)

   Infratentorial

172 (10%)

61 (9%)

111 (13%)

94 (9%)

78 (16%)

150 (11%)

22 (11%)

Hematoma volume, median (IQR)

15 (6–32)

12 (5–25)

18 (8–40)

 < 0.001

15 (6–30)

17 (6–40)

0.017

15 (6–33)

14 (6–30)

0.591

IVH extension, n (%)

584 (32%)

217 (32%)

367 (43%)

 < 0.001

361 (36%)

223 (45%)

0.001

517 (39%)

67 (33%)

0.058

Pre-stroke anti-hyperglycemic therapy, n (%)

162 (9%)

90 (13%)

72 (8%)

 < 0.001

99 (9%)

63 (10%)

0.661

147 (10%)

15 (6%)

0.034

Post-stroke anti-hyperglycemic therapy, n (%)

296 (16%)

170 (23%)

126 (12%)

 < 0.001

205 (19%)

91 (13%)

0.001

258 (17%)

38 (14%)

0.124